WELS:XETRA:XETRA-Amundi S&P Global Health Care ESG UCITS ETF DR EUR Acc (EUR)

ETF | Others |

Last Closing

USD 11.116

Change

-0.03 (-0.29)%

Market Cap

USD 0.24B

Volume

7.62K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.13 (+0.26%)

USD 473.61B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.10 (+0.62%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.20 (+0.77%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.20 (+0.74%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.07 (+0.28%)

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

+1.30 (+0.80%)

USD 126.93B
JARI:XETRA Amundi Index Solutions - Amund..

+0.30 (+0.69%)

USD 101.50B
8R80:XETRA Amundi Index Solutions - Amund..

+0.16 (+0.11%)

USD 99.29B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.31 (+0.63%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+3.08 (+0.58%)

USD 80.38B

ETFs Containing WELS:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.21% 57% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.21% 57% F 58% F
Trailing 12 Months  
Capital Gain 9.11% 50% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.11% 50% F 53% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.68% 44% F 44% F
Dividend Return 2.68% 44% F 42% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5.11% 84% B 88% B+
Risk Adjusted Return 52.48% 63% D 66% D+
Market Capitalization 0.24B 52% F 46% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.